Amgen Cops To Aranesp Misbranding, Will Pay $762M

Law360, New York (December 18, 2012, 5:11 PM EST) -- Amgen Inc. pled guilty in New York federal court Tuesday to misbranding its Aranesp anemia drug and agreed to a combined $762 million civil and criminal payout to resolve long-running allegations about its sales and marketing practices.

Federal prosecutors said Amgen, the world's largest biotech firm, would pay $150 million in criminal forfeitures and penalties for marketing the drug to health care providers for unapproved uses. Meanwhile, attorneys involved in several related civil whistleblower lawsuits said the company had agreed to an additional $612 million in...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.